Turning an epigenetic enzyme the industry called undruggable into an oral pill - one that is now being tested in cancer patients.
For two decades, cancer researchers knew that an enzyme called NSD2 - also known by the blunt acronym MMSET, for Multiple Myeloma SET domain - helped drive some of the most stubborn tumors. Knowing was the easy part. Drugging it was another matter. NSD2 belongs to a family of proteins that write chemical marks onto chromatin, the packaging that decides which genes a cell switches on. Interfere clumsily and you risk the whole system. So the target sat on shelves, filed under "too hard."
K36 Therapeutics was built to take it off the shelf. Launched in 2021 by Atlas Venture and F-Prime Capital, the company's premise is narrow and specific: design a small molecule that selectively blocks NSD2, lower the epigenetic mark it deposits (called H3K36me2), and let the tumor's gene-expression program return toward normal. Do that, the thesis goes, and cancer cells that had learned to resist treatment become sensitive again.
The name is a tell. "K36" points straight at H3K36 - the histone lysine 36 methylation site its drugs are engineered to quiet. It is the rare company whose brand is also its mechanism of action.
NSD2 inhibition is not a bigger hammer. It is a different tool - resetting the epigenetic signal rather than attacking the cell head-on.
K36 runs a focused pipeline: two oral, selective NSD2 inhibitors aimed at different diseases that share the same underlying biology. The strategy is disciplined - when you understand the target deeply enough, the same key can open more than one door.
A first-in-class, oral, selective NSD2/MMSET inhibitor for relapsed or refractory multiple myeloma in patients carrying the t(4;14) translocation - roughly one in five myeloma cases, and a high-risk subtype. Tested alone and in combination with carfilzomib, mezigdomide or pomalidomide.
Trial: K36-MMSET-001An oral, selective NSD2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC). Evaluated as monotherapy and in combination with darolutamide, an androgen receptor inhibitor - extending K36's epigenetic approach into solid tumors.
Trial: STRIKE-001 (NCT07103018)K36's ultimate customers are patients - specifically the roughly 20% of multiple myeloma patients whose disease carries the t(4;14) translocation, and men with metastatic castration-resistant prostate cancer. Its immediate community is the hematology and oncology field: trial investigators, clinical sites, and the researchers watching whether NSD2 inhibition pays off.
Cancer adapts and grows resistant to standard drugs. The t(4;14) subtype in particular carries worse odds. By resetting the epigenetics that fuel resistance, K36 aims to give these patients a mechanism no existing therapy offers.
Most biotechs crowd around the same fashionable targets. K36 went the other way - toward a lonely, difficult one. Its differentiation is simply being first: gintemetostat is believed to be the first NSD2 inhibitor ever tested in cancer patients.
And it did the sequencing in the right order. Rather than build a drug and hunt for patients, K36 started with a genetic biomarker - t(4;14) - and engineered a molecule for exactly that population. That is precision oncology as it is meant to be practiced.
K36 is a venture-backed, clinical-stage R&D company. It earns no product revenue yet; instead it funds operations through equity financings and creates value by advancing candidates toward clinical proof-of-concept - the point at which a partnership, licensing deal, or acquisition becomes possible.
The 2023 Series B - led by Nextech Invest with strategic participation from Bristol Myers Squibb - was earmarked to fund clinical proof-of-concept for KTX-1001. It is a notable vote of confidence for a company of roughly 13 employees working on a first-in-class mechanism.
F-Prime and Atlas Venture, with Eight Roads, found K36 to drug the epigenetic target NSD2/MMSET.
Nextech Invest leads, with Bristol Myers Squibb, to fund clinical proof-of-concept for KTX-1001.
K36 presents its first clinical KTX-1001 data across multiple posters at the 66th ASH Annual Meeting.
The KTX-2001 prostate trial opens, first-in-human gintemetostat data lands at ASH 2025, and Dr. Shinta Cheng joins as Chief Medical Officer.
K36 completes dosing of the first KTX-2001 cohort and presents the STRIKE-001 study design at ASCO GU 2026.